This site is intended only for healthcare professionals resident in the Republic of Ireland

Search

Menu

Close

Sign in or RegisterLog out
Our medicinesTherapy areasExplore contentExplore contentMaterialsVideosPodcastsLet’s connectLet's connectContact usSign up

Menu

Close

AboutIndicationsBroad CoverageEfficacyEfficacyLimited Treatment OptionsSafetySafety

Safety Profile Summary 

DosingAdult DosingPaediatric Dosing

Prescribing Information

IndicationsTherapeutic Indications

ZAVICEFTA(ceftazidime-avibactam) is indicated for the treatment of adult and paediatric patients from birth with the following infections:1*

Complicated urinary tract infection  (cUTI), including pyelonephritis

Complicated intra-abdominal infection (cIAI)

Hospital-acquired pneumonia, including ventilator-associated pneumonia
(HAP/VAP)

Infections due to aerobic Gram-negative organisms in patients with limited treatment options†

ZAVICEFTA is also indicated for the treatment of adult patients with bacteraemia that occurs in association with, or is suspected to be 
associated with, cUTI, cIAI or HAP/VAP

*Consideration should be given to official guidance on the appropriate use of antibacterial agents.1 
†Data support the use of ZAVICEFTA in adult patients with limited treatment options including in primary bacteraemia, cSSTI, BJI, meningitis, febrile neutropenia, cystic fibrosis, post-transplant patients due to KPC and OXA-48 resistance mechanisms, and MDR Pseudomonas.2-16

Prescribing information

Zavicefta® (avibactam sodium, ceftazidime pentahydrate)

Zavicefta® (avibactam sodium, ceftazidime pentahydrate) 2g/0.5g powder for concentrate 
for solution for infusion)

Abbreviations:BJI, bone and joint infection; cIAI, complicated intra-abdominal infection; cSSTI, complicated skin and soft-tissue infection; cUTI, complicated urinary tract infection; HAP, hospital-acquired pneumonia; KPC, Klebsiella pneumoniae carbapenemase; MDR, multidrug-resistant; OXA, oxacillinase; VAP, ventilator-associated pneumonia.
References:

ZAVICEFTA. Summary of Product Characteristics.

Castón JJ, et al. Int J Infect Dis 2017;59:118–23.van Duin D, et al. Clin Infect Dis 2018;66:163–71.Sousa A, et al. J Antimicrob Chemother 2018;73:3170–5.Temkin E, et al. Antimicrob Agents Chemother 2017;61:e01964-16.Shields RK, et al. Antimicrob Agents Chemother 2017;61:e00883-17.Tumbarello M, et al. Clin Infect Dis 2019;68:355–64.Tumbarello M, et al. Clin Infect Dis 2021;10.1093/cid/ciab176.Tsolaki V, et al. Antimicrob Agents Chemother 2020;64:e02320-19.Rathish B, et al. Cureus 2021;13:e13081.Atkin SD, et al. Infect Drug Resist 2018;11:1499–510.Chen W, et al. Ann Transl Med 2020;8:39.Jabbour JF, et al. Curr Opin Infect Dis 2020;33:146–54.Aguado JM, et al. Transplant Rev (Orlando) 2018;32:36–57.Soriano A, et al. Infect Dis Ther 2021:1–46.Mazuski JE, et al. Infect Dis Ther 2021:1–16.About 

Legal Category: S1A

Further information available upon request
PP-ZVA-IRL-0283. December 2024

Adverse events should be reported.

If you wish to make a medical information inquiry or report an adverse event please contact Pfizer on 1800 633 363 
or email Pfizer at [email protected] or visit www.PfizerMedicalInformation.ie

Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

PfizerPro AccountPfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Sign in or RegisterRegisterAccountLog out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

 

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3.  Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.  

 

Copyright © 2024 Pfizer Limited. All rights reserved.
 

PP-UNP-IRL-0891. February 2025
For Healthcare Professionals in the Republic of Ireland *

The information on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland and contains promotional content.

I confirm that I am a healthcare professional* resident in the Republic of Ireland.

If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland Unlimited Company.

*The IPHA Code definition of a healthcare professional is a person of any of the following classes: (i) Registered medical practitioners (ii) Registered dentists (iii) Registered pharmacists (iv) Registered nurses

Terms of use

PP-UNP-IRL-0891. February 2025

Yes No
You are now leaving PfizerPro
You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.


PP-UNP-IRL-0891. February 2025